Renal Cell Carcinoma the Executives: A Stage to Nano-Chemoprevention
Received Date: Sep 04, 2023 / Published Date: Sep 30, 2023
Abstract
Renal cell carcinoma (RCC) is one of the most well-known kidney diseases, liable for almost 90 % of every single renal threat. Notwithstanding the accessibility of numerous treatment techniques, RCC actually remains a hopeless illness because of its resistance to customary treatments. Nanotechnology is an emerging area of science that offers fresher prospects in therapeutics including malignant growth medication, explicitly by designated conveyance of anticancer medications. A few phytochemicals are known for their enemy of malignant growth properties and have been viewed as chemopreventive specialists. In any case, the hydrophobic idea of numerous phytochemicals diminishes their bioavailability and appropriation, accordingly showing restricted remedial impact. The use of nanotechnology to upgrade chemoprevention is a powerful methodology to expand the bioavailability of phytochemicals and accordingly their helpful adequacy. The current audit centers around the utility of nanotechnology in RCC treatment and chemopreventive specialists of RCC. We have likewise pictured what’s to come possibilities of nanomolecules in the avoidance and fix of RCC.
Citation: Tete S (2023) Renal Cell Carcinoma the Executives: A Stage to Nano- Chemoprevention. Adv Cancer Prev 7: 186. Doi: 10.4172/2472-0429.1000186
Copyright: © 2023 Tete S. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Share This Article
Recommended Conferences
42nd Global Conference on Nursing Care & Patient Safety
Toronto, CanadaRecommended Journals
Open Access Journals
Article Tools
Article Usage
- Total views: 673
- [From(publication date): 0-2023 - Dec 22, 2024]
- Breakdown by view type
- HTML page views: 583
- PDF downloads: 90